Astragaloside II(Synonyms: Astrasieversianin VIII)

天然产物 糖类和糖苷 Saccharides and Glycosides

Astragaloside II (Synonyms: Astrasieversianin VIII) 纯度: ≥98.0%

黄芪皂苷II (Astragaloside II) 是从黄芪中分离到的一种天然化合物。

Astragaloside II(Synonyms: Astrasieversianin VIII)

Astragaloside II Chemical Structure

CAS No. : 84676-89-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1640 In-stock
5 mg ¥1000 In-stock
10 mg ¥1800 In-stock
50 mg ¥5400 In-stock
100 mg ¥9200 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Astragaloside II 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Natural Product Library
  • Glycoside Compound Library
  • Medicine Food Homology Compound Library
  • Terpenoids Library
  • Traditional Chinese Medicine Monomer Library

生物活性

Astragaloside II is a natural isolated from Astragalus. IC50 value: Target: In vitro: In vivo: The developed and validated method has been successfully applied to the quantification and pharmacokinetic study of AST II in rats after intravenous and oral administration of AST II. The oral absolute bioavailability (F) of AST II was calculated to be 0.79 ± 0.16% with an elimination half-life (t1/2) value of 1.92 ± 0.30 h, suggesting its poor absorption and/or strong metabolism in vivo [1].

分子量

827.01

Formula

C43H70O15

CAS 号

84676-89-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (120.92 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2092 mL 6.0459 mL 12.0918 mL
5 mM 0.2418 mL 1.2092 mL 2.4184 mL
10 mM 0.1209 mL 0.6046 mL 1.2092 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.02 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.02 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.02 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Haijun Qu, et al. Quantification and pharmacokinetics of astragaloside II in rats by rapid liquid chromatography-tandem mass spectrometry. Anal. Methods, 2014,6, 6815-6822

    [2]. Kong XH, et al. Astragaloside II induces osteogenic activities of osteoblasts through the bone morphogenetic protein-2/MAPK and Smad1/5/8 pathways. Int J Mol Med. 2012 Jun;29(6):1090-8.

    [3]. Huang C, et al. Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol. 2012 Dec;64(12):1741-50.

    [4]. Wan CP, et al. Astragaloside II triggers T cell activation through regulation of CD45 protein tyrosine phosphatase activity. Acta Pharmacol Sin. 2013 Apr;34(4):522-30.

Astragaloside IV(Synonyms: 黄芪皂苷 IV)

天然产物 糖类和糖苷 Saccharides and Glycosides

Astragaloside IV;(Synonyms: 黄芪皂苷 IV) 纯度: ge;98.0%

Astragaloside IV 是从黄芪中分到的皂苷类物质,能够抑制 ERK1/2JNK 的激活,在乳腺癌细胞 MDA-MB-231 中,能够下调 (MMP)-2,(MMP)-9 的信号通路。

Astragaloside IV(Synonyms: 黄芪皂苷 IV)

Astragaloside IV Chemical Structure

CAS No. : 84687-43-4

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg) ; Apply now ;
10;mM;*;1 mL in DMSO ¥550 In-stock
10 mg ¥500 In-stock
50 mg ¥1500 In-stock
100 mg ¥2400 In-stock
200 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Astragaloside IV 相关产品

bull;相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • Kinase Inhibitor Library
  • MAPK Compound Library
  • Metabolism/Protease Compound Library
  • Stem Cell Signaling Compound Library
  • Natural Product Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Differentiation Inducing Compound Library
  • Reprogramming Compound Library
  • Glycoside Compound Library
  • Oxygen Sensing Compound Library
  • Medicine Food Homology Compound Library
  • Terpenoids Library
  • Glutamine Metabolism Compound Library
  • Traditional Chinese Medicine Monomer Library
  • FDA Approved amp; Pharmacopeial Drug Library
  • Anti-Breast Cancer Compound Library
  • Anti-Lung Cancer Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Parkinson’s Disease Compound Library
  • Anti-Obesity Compound Library
  • Angiogenesis Related Compound Library
  • Transcription Factor Targeted Library
  • Anti-Liver Cancer Compound Library
  • Anti-Colorectal Cancer Compound Library

生物活性

Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells.

IC50 Target[4]

MMP-2

;

MMP-9

;

ERK1

;

ERK2

;

JNK

;

体外研究
(In Vitro)

Astragaloside IV (10, 20, 40 ng/mL) inhibits NSCLC cell growth, whereas low concentrations of astragaloside IV (1, 2.5, 5 ng/mL) has no obvious cytotoxicity on cell viability. Moreover, combined treatment with astragaloside IV significantly increases chemosensitivity to cisplatin in NSCLC cells. On the molecular level, astragaloside IV co-treatment significantly inhibits the mRNA and protein levels of B7-H3 in the presence of cisplatin[2]. Astragaloside IV inhibits the viability and invasive potential of MDA-MB-231 breast cancer cells, suppresses the activation of the mitogen activated protein kinase (MAPK) family members ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2 and -9[4].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Astragaloside IV (10, 20 mg/kg, p.o.) exhibits a potent ability to prevent cognitive deficits induced by transient cerebral ischemia and reperfusion. Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) can significantly decrease the levels of these cytokines compared to the Model group. Astragaloside IV significantly inhibits the level of TLR4 and its downstream proteins, suggesting that both MyD88-dependent and -independent pathways play important roles in the anti-inflammatory effects of Astragaloside IV. Astragaloside IV attenuates NLRP3 and cleaved-caspase-1 expression, and reduces Iba1 protein expression[1]. In the mice model, the high-dose astragaloside IV group has a significant increase in the 48-hour survival rate [60% (9/15) vs 13.3% (2/15), P < 0.05], significant reductions in the serum ALT and AST levels (P < 0.01), and significant reductions in liver histopathological indices and the degree of apoptosis of hepatocytes (P < 0.01), as well as a significant reduction in the content of MDA in liver homogenate (P < 0.01) and a significant increase in the activity of SOD[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

784.97

Formula

C41H68O14

CAS 号

84687-43-4

中文名称

黄芪皂苷 IV;黄芪甙

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20deg;C 3 years
4deg;C 2 years
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

DMSO : ≥ 100 mg/mL (127.39 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2739 mL 6.3697 mL 12.7393 mL
5 mM 0.2548 mL 1.2739 mL 2.5479 mL
10 mM 0.1274 mL 0.6370 mL 1.2739 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: 2.5 mg/mL (3.18 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (3.18 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.18 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.18 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Li M, et al. Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms. Neurosci Lett. 2016 Dec 20. pii: S0304-3940(16)30994-

    [2]. He CS, et al. Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3. Cell Physiol Biochem. 2016;40(5):1221-1229. Epub 2016 Dec 14.

    [3]. Liu L, et al. [Protective effect of astragaloside IV against acute liver failure in experimental mice]. Zhonghua Gan Zang Bing Za Zhi. 2016 Oct 20;24(10):772-777

    [4]. Jiang K, et al. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol. 2016 Dec 5;42:195-20

Kinase Assay
[4]

Briefly, MDA-MB-231 cells treated as indicated or tumor tissues are harvested and lysed in Mg2+ lysis buffer containing 50 mM Tris (pH 7.5), 10 mM MgCl2, 0.5 M NaCl, and protease inhibitor cocktail. Equal amounts of lysates are incubated with PAK-PBD beads at 4°C for 1 h. PAK-PBD beads are pelleted by centrifugation and washed with ish buffer containing 25 mM Tris (pH 7.5), 30 mM MgCl2, 40 mM NaCl. Active Rac1 is detected by western blotting.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[2]

Cell viability is determined by CCK-8 assay. To be brief, cultured NSCLC cells are seeded into 96-well plates at the density of 4×104 (cells/well). Then 10 µL⁄well CCK8 solution is added and incubated in dark at 37°C for another 2 h. The absorbance is determined with the wavelength of 490 nm.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Transient cerebral ischemia and reperfusion is prepared by BCCAO, as BCCAO is considered an ideal model to study transient cerebral ischemia and reperfusion injury-mediated inflammatory response. Mice are randomLy divided into the Sham, Model, Astragaloside IV (10 mg/kg) and Astragaloside IV (20 mg/kg) treatment groups. The Astragaloside IV treatment groups are intragastrically administered 7 days before the surgery and terminated on the day of sacrifice. On the day of the surgery, Astragaloside IV is administrated 2 h prior to ischemia. The Sham-operated and Model groups are treated with distilled water. After the mice are anesthetized with an intraperitoneal injection of chloral hydrate (350 mg/kg), the bilateral common carotid arteries are exposed and carefully separated with a small ventral neck incision and occluded twice (20 min each) with ligated surgical silk as described previously with minor modifications. There is a 10 min reperfusion period between the two occlusion periods (ischemia 20 min − reperfusion 10 min − ischemia 20 min). Sham-operated mice are subjected to the same surgical operation without the surgical silk ligation. Mouse body temperature is maintained at 37±0.5°C during the surgery with heating equipment until recovery from the anesthesia.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

参考文献
  • [1]. Li M, et al. Astragaloside IV attenuates cognitive impairments induced by transient cerebral ischemia and reperfusion in mice via anti-inflammatory mechanisms. Neurosci Lett. 2016 Dec 20. pii: S0304-3940(16)30994-

    [2]. He CS, et al. Astragaloside IV Enhances Cisplatin Chemosensitivity in Non-Small Cell Lung Cancer Cells Through Inhibition of B7-H3. Cell Physiol Biochem. 2016;40(5):1221-1229. Epub 2016 Dec 14.

    [3]. Liu L, et al. [Protective effect of astragaloside IV against acute liver failure in experimental mice]. Zhonghua Gan Zang Bing Za Zhi. 2016 Oct 20;24(10):772-777

    [4]. Jiang K, et al. Astragaloside IV inhibits breast cancer cell invasion by suppressing Vav3 mediated Rac1/MAPK signaling. Int Immunopharmacol. 2016 Dec 5;42:195-20

Astragaloside III(Synonyms: 黄芪皂苷 III)

天然产物 糖类和糖苷 Saccharides and Glycosides

Astragaloside III (Synonyms: 黄芪皂苷 III) 纯度: 98.89%

黄芪皂苷III (Astragaloside III)是从黄芪中分离到的一种天然产物。

Astragaloside III(Synonyms: 黄芪皂苷 III)

Astragaloside III Chemical Structure

CAS No. : 84687-42-3

规格 价格 是否有货 数量
5 mg ¥2500 In-stock
10 mg ¥4200 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Astragaloside III 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Natural Product Library
  • Glycoside Compound Library
  • Medicine Food Homology Compound Library
  • Terpenoids Library
  • Traditional Chinese Medicine Monomer Library

生物活性

Astragaloside III is a natural product isolated from Astragalus.

分子量

784.97

Formula

C41H68O14

CAS 号

84687-42-3

中文名称

黄芪皂苷 III

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (63.70 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.2739 mL 6.3697 mL 12.7393 mL
5 mM 0.2548 mL 1.2739 mL 2.5479 mL
10 mM 0.1274 mL 0.6370 mL 1.2739 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.18 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (3.18 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (3.18 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (3.18 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. SHI Jing-chao, et al. Determination of Astragaloside III and Astragaloside IV in Astragalus with HPLC-ELSD Method. World Journal of Integrated Traditional and Western Medicine, 2014-07

Astragaloside VI

天然产物 糖类和糖苷 Saccharides and Glycosides

Astragaloside VI  纯度: 99.95%

Astragaloside VI 可通过激活表皮生长因子受体/细胞外信号调节激酶 (EGFR/ERK) 信号通路来加速伤口愈合。

Astragaloside VI

Astragaloside VI Chemical Structure

CAS No. : 84687-45-6

规格 价格 是否有货 数量
5 mg ¥5390 In-stock
10 mg   询价  
50 mg   询价  

* Please select Quantity before adding items.

Astragaloside VI 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Immunology/Inflammation Compound Library
  • JAK/STAT Compound Library
  • Kinase Inhibitor Library
  • Protein Tyrosine Kinase Compound Library
  • Natural Product Library
  • Glycoside Compound Library
  • Anti-Hepatitis C Virus Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Angiogenesis Related Compound Library

生物活性

Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing.

IC50 & Target[1][2]

EGFR

 

体外研究
(In Vitro)

Pretreatment with Astragaloside VI (AS-VI) at 1 μM increases EGFR activation in HaCaT cells. Astragaloside VI, a major intestinal metabolite of astragalosides, exerts the strongest EGFR activation. In HaCaT cells, the positive control, EGF expectedly results in 1.5±0.03-fold increase in cell proliferation, compared to the control. Astragaloside VI at the indicated concentrations also significantly promots cell proliferation in both HaCaT and HDF cells[1]. Astragaloside VI promotes neural stem cell proliferation and enhances neurological function recovery in transient cerebral ischemic injury via activating EGFR/MAPK signaling cascades[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Astragaloside VI improves wound healing, compared to the control. In the simple noninfected wound model, wound healing in mice is accelerated by Astragaloside VI, where in the time required for wound closure is shortened by approximately 2-4 days, compared to that in the control group. Topical treatment with Astragaloside VI reduces the volume of pus produced, compared to the control group. Astragaloside VI treated wounds show an accelerated rate of healing, compared to the control and vaseline groups. By day 22, the Astragaloside VI -treated wounds fully close, whereas the blank and vaseline-treated wounds do not fully close until day 26. Angiogenesis is a crucial step in the formation of granulation tissue and wound healing. Astragaloside VI increases blood vessel formation in both the non-infected and infected wound models[1]. Astragaloside VI could effectively activate EGFR/MAPK signaling cascades, promote NSCs proliferation and neurogenesis in transient cerebral ischemic brains, and improve the repair of neurological functions in post-ischemic stroke rats[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

947.11

Formula

C47H78O19

CAS 号

84687-45-6

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 100 mg/mL (105.58 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.0558 mL 5.2792 mL 10.5584 mL
5 mM 0.2112 mL 1.0558 mL 2.1117 mL
10 mM 0.1056 mL 0.5279 mL 1.0558 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.64 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.64 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (2.64 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (2.64 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Lee SY, et al. Astragaloside VI and cycloastragenol-6-O-beta-D-glucoside promote wound healing in vitro and in vivo. Phytomedicine. 2018 Jan 1;38:183-191.

    [2]. Chen X, et al. Astragaloside VI Promotes Neural Stem Cell Proliferation and Enhances Neurological Function Recovery in Transient Cerebral Ischemic Injury via Activating EGFR/MAPK Signaling Cascades. Mol Neurobiol. 2018 Aug 7.

Astragaloside I(Synonyms: Astrasieversianin IV; Cyclosieversioside B)

天然产物 糖类和糖苷 Saccharides and Glycosides

Astragaloside I (Synonyms: Astrasieversianin IV; Cyclosieversioside B) 纯度: ≥98.0%

Astragaloside I 是从黄芪中分离出来的一种天然化合物。Astragaloside I 可通过 Wnt/β-catenin 信号通路刺激成骨细胞分化,具有成骨的活性。

Astragaloside I(Synonyms: Astrasieversianin IV;  Cyclosieversioside B)

Astragaloside I Chemical Structure

CAS No. : 84680-75-1

规格 价格 是否有货 数量
10 mM * 1 mL in DMSO ¥1721 In-stock
5 mg ¥1000 In-stock
10 mg ¥1800 In-stock
50 mg ¥5400 In-stock
100 mg ¥9200 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Astragaloside I 相关产品

相关化合物库:

  • Natural Product Library Plus
  • Bioactive Compound Library Plus
  • Stem Cell Signaling Compound Library
  • Wnt/Hedgehog/Notch Compound Library
  • Natural Product Library
  • Anti-Aging Compound Library
  • Glycoside Compound Library
  • Medicine Food Homology Compound Library
  • Terpenoids Library
  • Cytoskeleton Compound Library
  • Traditional Chinese Medicine Monomer Library
  • Neuroprotective Compound Library
  • Transcription Factor Targeted Library

生物活性

Astragaloside I, one of the main active ingredients in Astragalus membranaceus, has osteogenic properties. Astragaloside I stimulates osteoblast differentiation through the Wnt/β-catenin signaling pathway[1].

体外研究
(In Vitro)

Astragaloside I (10-40 μM) upregulates the express of β-catenin, Runx2, BGP and OPG, RANKL (osteogenesis marker genes) in MC3T3-E1 cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1].

Cell Line: MC3T3-E1 cells.
Concentration: 0, 10, 20, 40 μM.
Incubation Time: 5 days.
Result: Stimulated the expression of β-catenin and Runx2.

Cell Cytotoxicity Assay[1].

Cell Line: MC3T3-E1 cells.
Concentration: 0, 10, 20, 40 μM.
Incubation Time: 1, 3 or 6 days (The media was changed every 2 days).
Result: No obvious cytotoxic effect was observed in the MC3T3-E1 cells.

分子量

869.04

Formula

C45H72O16

CAS 号

84680-75-1

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 50 mg/mL (57.53 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.1507 mL 5.7535 mL 11.5070 mL
5 mM 0.2301 mL 1.1507 mL 2.3014 mL
10 mM 0.1151 mL 0.5753 mL 1.1507 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 3.25 mg/mL (3.74 mM); Clear solution

    此方案可获得 ≥ 3.25 mg/mL (3.74 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 32.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂: 10% DMSO    90% corn oil

    Solubility: ≥ 3.25 mg/mL (3.74 mM); Clear solution

    此方案可获得 ≥ 3.25 mg/mL (3.74 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 32.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Xun Cheng, et al. Astragaloside I Stimulates Osteoblast Differentiation Through the Wnt/β-catenin Signaling Pathway. Phytother Res. 2016 Oct;30(10):1680-1688.

Astragaloside

天然产物 糖类和糖苷 Saccharides and Glycosides

Astragaloside;

Astragaloside 保护大鼠海马形态结构,恢复乙酰胆碱水平,并通过使脑电图(EEG)正常化改善脑功能。

Astragaloside

Astragaloside Chemical Structure

CAS No. : 17429-69-5

规格 是否有货
5 mg 询价
10 mg 询价
25 mg 询价

* Please select Quantity before adding items.

生物活性

Astragaloside protects the morphological structures and restores acetylcholine level in rat hippocampus, and improves brain functions via normalizing brain EEG[1].

分子量

640.54

Formula

C28H32O17

CAS 号

17429-69-5

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Zhao L, et al. Astragaloside protects rat brain from microwave-induced functional injuries via restoring acetylcholine and normalizing electroencephalogram. Environ Sci Pollut Res Int. 2020;27(32):40787-40794.